Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) announced management will present at three investor conferences in March and April 2026. Presenters include CEO Mark Velleca, M.D., Ph.D. and CSO Elizabeth Buck, Ph.D.

Scheduled presentations: TD Cowen Healthcare Conference on Mar 4, 2026 at 1:10pm ET, Needham Virtual Healthcare Conference on Apr 15, 2026 at 3:00pm ET, and investor meetings at Raymond James BioPharma on Apr 14, 2026. Webcasts and 90-day archived replays will be available via the company investor relations site.

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D. and Chief Scientific Officer Elizabeth Buck, Ph.D., are as follows:

• 46th Annual TD Cowen Healthcare Conference presentation at 1:10pm ET on Wednesday, March 4, 2026
• 25th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Wednesday, April 15, 2026

Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days. The Company will also meet with investors at the Raymond James BioPharma Conference on Tuesday, April 14, 2026.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing silevertinib, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts

For Investors:
investors@bdtx.com

For Media:
media@bdtx.com

FAQ

When will Black Diamond Therapeutics (BDTX) present at the TD Cowen Healthcare Conference?

BDTX will present at the TD Cowen Healthcare Conference on March 4, 2026 at 1:10pm ET. According to the company, the presentation will be webcast live and archived on its investor relations website for 90 days after airing.

How can investors watch Black Diamond Therapeutics (BDTX) presentations from March–April 2026?

Investors can watch live webcasts on the company investor relations website at presentation start times. According to the company, replays will be archived on the site for 90 days after each presentation.

Who will present for Black Diamond Therapeutics (BDTX) at the upcoming investor conferences?

Presenters include CEO Mark Velleca, M.D., Ph.D. and CSO Elizabeth Buck, Ph.D.. According to the company, both will cover clinical programs and company updates during the scheduled sessions.

When is Black Diamond Therapeutics (BDTX) scheduled to present at the Needham Virtual Healthcare Conference?

BDTX is scheduled to present at the Needham Virtual Healthcare Conference on April 15, 2026 at 3:00pm ET. According to the company, the presentation will be available via live webcast and a 90-day archived replay.

Will Black Diamond Therapeutics (BDTX) meet investors at Raymond James BioPharma in April 2026?

Yes, the company will meet with investors at the Raymond James BioPharma Conference on April 14, 2026. According to the company, these will be investor meetings separate from the scheduled webcasts and presentations.